Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Thomaslchim claims to an ONCY director- NOT !
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(513)
•••
Comment by Lesalpes29on Jan 29, 2023 6:02pm
106 Views
Post# 35253066

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Thomaslchim claims to an ONCY director- NOT !

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Thomaslchim claims to an ONCY director- NOT !
fox7mf wrote: If you peruse the Tsoi board on Stocktwits, you quickly see that this Thomas has little in the way of support...only detractors. Some have even joined the conversation on the Oncy board, to warn that he is desperate & looking for support for the failing company. Anywho, let's get some news this week (accelerated approval), and then let's get our $8b-$10b buyout by mid-March. Good luck longs, and go Bengals!!!! And Onc!!!!!
I love the Bengals too! Against the Eagles it seems. If this Thomas I. is real probably that buyout is a case closed!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities